Subtypes of invasive intracholecystic papillary-tubular neoplasms: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.
4 affiliations
- 1The First Clinical Medical College of Gannan Medical University, Ganzhou, China.
- 2Department of General Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
- 3Research Center for Pharmaceutical Big Data and Bioinformatics, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
- 4School of Basic Medicine, Gannan Medical University, Ganzhou, China.
Abstract
The clinicopathologic and prognostic heterogeneity of invasive intracholecystic papillary-tubular neoplasm (ICPN) remains poorly characterized. Epidemiologic trends and survival differences between its major subtypes require further elucidation. This study aimed to compare the incidence trends, mortality, and survival outcomes between gallbladder papillary adenocarcinoma (GPA) and gallbladder mucinous adenocarcinoma (GMA). This population-based cohort study included 604 patients with invasive ICPN [2000-2022] from the Surveillance, Epidemiology, and End Results (SEER) database. Incidence and mortality trends were analyzed using Joinpoint regression. Propensity score matching (PSM; 1:1) was used to balance baseline characteristics. Survival was compared by Kaplan-Meier and log-rank tests. Prognostic factors were identified using multivariable Cox regression. Incidence and incidence-based mortality (IBM) of ICPN decreased significantly [annual percentage change (APC) =-5.5%, P<0.001; APC =-2.9%, P<0.05]. After PSM (n=342), GPA was associated with longer overall survival (OS) (41.0 vs. 22.0 months) and cancer-specific survival (CSS) (113.0 vs. 30.0 months) (both P=0.002). GMA was an independent risk factor for poor OS [hazard ratio (HR) =1.554] and CSS (HR =1.725) (both P<0.001), along with high tumor grade, advanced T stage, nodal and distant metastasis. Subgroup analysis showed that chemotherapy was associated with improved OS and CSS in GMA (HR =0.409; HR =0.366, both P<0.001) but not in GPA, suggesting a subtype-specific association. T-stage stratification confirmed that chemotherapy benefited only T3/T4 GMA patients (both P<0.001). Incidence and mortality of invasive ICPN have declined over the past 22 years. GPA carries a significantly better prognosis than GMA. Adjuvant chemotherapy may be associated with improved survival specifically for T3/T4 stage GMA, suggesting that subtype- and stage-tailored management warrants further investigation in prospective studies.
Related
- Discontinuing Surveillance of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms in Routine Practice: An External Application of the "Trivial" Criteria and the Resources it Would Release in Fourteen Health Systems.
- Distinct Progression Paths Underlie the Diversity of Pancreatic Papillary Cystic Neoplasms
- Plasma Protein Corona Fingerprinting Across Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma: A Comparative Proof-of-Concept Study
- Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study
- Long term (over five-year) outcomes of thermal ablation vs surgical resection for T1N0M0 papillary thyroid carcinoma in danger triangle: a propensity-matched dual-center study
BibTeX
@article{huang2026subtypes,
title = {{Subtypes of invasive intracholecystic papillary-tubular neoplasms: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.}},
author = {Jian Huang and Shu-Ni Zhou and Yu Liu and Wei Liu and Dong-Quan Lin and Juan Luo and Ping Hou},
journal = {Journal of gastrointestinal oncology},
year = {2026},
month = aug,
doi = {10.21037/jgo-2026-0619},
url = {https://europepmc.org/article/MED/42996601},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Subtypes of invasive intracholecystic papillary-tubular neoplasms: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.
AU - Jian Huang
AU - Shu-Ni Zhou
AU - Yu Liu
AU - Wei Liu
AU - Dong-Quan Lin
AU - Juan Luo
AU - Ping Hou
PY - 2026
DA - 2026/08/21
JO - Journal of gastrointestinal oncology
DO - 10.21037/jgo-2026-0619
UR - https://europepmc.org/article/MED/42996601
AB - The clinicopathologic and prognostic heterogeneity of invasive intracholecystic papillary-tubular neoplasm (ICPN) remains poorly characterized. Epidemiologic trends and survival differences between its major subtypes require further elucidation. This study aimed to compare the incidence trends, mortality, and survival outcomes between gallbladder papillary adenocarcinoma (GPA) and gallbladder mucinous adenocarcinoma (GMA). This population-based cohort study included 604 patients with invasive ICPN [2000-2022] from the Surveillance, Epidemiology, and End Results (SEER) database. Incidence and mortality trends were analyzed using Joinpoint regression. Propensity score matching (PSM; 1:1) was used to balance baseline characteristics. Survival was compared by Kaplan-Meier and log-rank tests. Prognostic factors were identified using multivariable Cox regression. Incidence and incidence-based mortality (IBM) of ICPN decreased significantly [annual percentage change (APC) =-5.5%, P<0.001; APC =-2.9%, P<0.05]. After PSM (n=342), GPA was associated with longer overall survival (OS) (41.0 vs. 22.0 months) and cancer-specific survival (CSS) (113.0 vs. 30.0 months) (both P=0.002). GMA was an independent risk factor for poor OS [hazard ratio (HR) =1.554] and CSS (HR =1.725) (both P<0.001), along with high tumor grade, advanced T stage, nodal and distant metastasis. Subgroup analysis showed that chemotherapy was associated with improved OS and CSS in GMA (HR =0.409; HR =0.366, both P<0.001) but not in GPA, suggesting a subtype-specific association. T-stage stratification confirmed that chemotherapy benefited only T3/T4 GMA patients (both P<0.001). Incidence and mortality of invasive ICPN have declined over the past 22 years. GPA carries a significantly better prognosis than GMA. Adjuvant chemotherapy may be associated with improved survival specifically for T3/T4 stage GMA, suggesting that subtype- and stage-tailored management warrants further investigation in prospective studies.
SN - 2078-6891
SN - 2219-679X
ER -